bs-12883R-PE [Conjugated Primary Antibody]
BRAF35 Polyclonal Antibody, PE Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: BRAF35

Immunogen Range: 1-100/317


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 10362

Source: KLH conjugated synthetic peptide derived from human BRAF35

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.

Conjugation: PE

Excitation/ Emission: 496,564nm/578nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)

Predicted Molecular Weight: 36


Cross Reactive Species: Mouse

Predicted Cross Reactive Species: Human
Rat
Cow

For research use only. Not intended for diagnostic or therapeutic use.